Atara Biotherapeutics, Inc. (ATRA) News

Atara Biotherapeutics, Inc. (ATRA): $4.94

-0.40 (-7.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 404

in industry

Filter ATRA News Items

ATRA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ATRA News Highlights

  • For ATRA, its 30 day story count is now at 12.
  • Over the past 29 days, the trend for ATRA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • SAGE, VRTX and DRUG are the most mentioned tickers in articles about ATRA.

Latest ATRA News From Around the Web

Below are the latest news stories about Atara Biotherapeutics Inc that investors may wish to consider to help them evaluate ATRA as an investment opportunity.

Is a Surprise Coming for Atara Biotherapeutics (ATRA) This Earnings Season?

Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 24, 2022

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Yahoo | February 24, 2022

Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Yahoo | February 23, 2022

Why Atara Biotherapeutics Stock Is Sinking Today

A fatality in an early-stage clinical trial is weighing on the cell therapy company's stock today.

Yahoo | February 18, 2022

Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial

Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara Biotherapeutics Inc's (NASDAQ: ATRA) autologous mesothelin CAR T, ATA2271. MSK has voluntarily paused enrollment of new patients in the study temporarily while additional information regarding the case is gathered and reviewed. ATA2271 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin currently under clin

Yahoo | February 18, 2022

Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial

SOUTH SAN FRANCISCO, Calif., February 18, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, developing transformative therapies for patients with cancer and autoimmune diseases, today reported Memorial Sloan Kettering Cancer Center’s (MSK) notification to the U.S. Food and Drug Administration (FDA) of a fatal serious adverse event (SAE) associated with a patient treated in the ongoing Phase 1, MSK-conducted dose-escalation clinical study of autologous mesothelin

Yahoo | February 18, 2022

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

SOUTH SAN FRANCISCO, Calif., February 17, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2021 financial results after market close on Monday, February 28, 2022. Following the release, the Company will host a live conference call and w

Yahoo | February 17, 2022

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., February 07, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 31,730 restricted stock units of Atara’s common stock to 10 newly hired employees and stock options to purchase an aggregate of 30,819 shares of Atara’s common stock to four such newly hired e

Yahoo | February 7, 2022

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is up 6.2%, while insiders who purchased US$500k are up 2.0%

Last week, Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) insiders, who had purchased shares in the previous 12 months...

Yahoo | January 29, 2022

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Atara Biotherapeutics (ATRA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vertex Pharmaceuticals (VRTX – Research Report) and Atara Biotherapeutics (ATRA – Research Report). Vertex Pharmaceuticals (VRTX) Needham analyst Joseph Stringer maintained a Hold rating on Vertex Pharmaceuticals today. The company's shares closed last Wednesday at $226.58. According to TipRanks.

Howard Kim on TipRanks | January 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.469 seconds.